Premium
Weight Reduction in Obese Adolescents With and Without Binge Eating
Author(s) -
BishopGilyard Chanelle T.,
Berkowitz Robert I.,
Wadden Thomas A.,
Gehrman Christine A.,
Cronquist Joanna L.,
Moore Reneé H.
Publication year - 2011
Publication title -
obesity
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.438
H-Index - 199
eISSN - 1930-739X
pISSN - 1930-7381
DOI - 10.1038/oby.2010.249
Subject(s) - disinhibition , medicine , weight loss , obesity , binge eating , percentile , depression (economics) , overweight , beck depression inventory , randomized controlled trial , body mass index , demography , psychiatry , anxiety , statistics , mathematics , economics , macroeconomics , sociology
Little is known about binge eating (BE) in adolescents. The primary aim of the present study was to examine the relationship between BE and weight loss in adolescents (BMI ≥95th percentile) enrolled in a randomized controlled trial of behavioral and pharmacologic treatment of obesity. Participants were 82 treatment‐seeking adolescents (BMI = 37.9 ± 3.8 kg/m 2 ; age = 14.1 ± 1.2 years; 67% females; 42% African American, 55% white). Participants completed the Children's Depression Inventory (CDI), the Piers Harris Self‐Esteem Questionnaire, and the Eating Inventory (including cognitive restraint, disinhibition, and hunger scales). BE was assessed by a questionnaire and a confirmatory interview. At baseline, 24% of participants met criteria for BE ( N = 13 met full BE disorder (BED) criteria; N = 7 met subthreshold BE). There were no significant differences in percentage reduction in initial BMI between participants with or without BE at month 6 (−7.0 ± 1.6 vs. −6.9 ± 0.9%) or month 12 (−8.8 ± 2.4 vs. −8.3 ± 1.3%) (omnibus main effect BE P = 0.89, interaction BE × time P = 0.84, interaction BE × drug P = 0.61). The rate of BE declined significantly over time from 24% ( n = 20) at baseline to 8% ( n = 6) at month 6 and 3% ( n = 2) at month 12 ( P = 0.003). There were significant decreases in hunger and disinhibition as well as an increase in cognitive restraint over time (all P ≤ 0.0001). Findings suggest a combination of behavioral and pharmacologic therapy may produce both weight loss and improvement in BE.